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SUMMARY
Injection site infections in injecting drug users (IDUs) are associated with serious morbidity and
healthcare costs. Factors associated with symptoms of these were examined through annual
(2006–2008) unlinked-anonymous survey of IDUs in England, Wales and Northern Ireland.
Overall 36% (1863/5209) self-reported having a symptom with no trend over time (35% 2006,
37% 2007, 34% 2008). Symptoms were less common in the North East of England; increased
with years injecting ; and were higher in women, those recently homeless, those recently using a
needle exchange, and those injecting both opiates and stimulants. Of those injecting during the
previous 4 weeks (n=3733) symptoms were associated with: injecting daily ; injectingo10 times a
day; injecting into hands, groin, or legs ; sharing ﬁlters; and reusingwater to ﬂush syringes. Symptoms
of injection site infections are common in IDUs. Better-targeted preventive interventions are
needed, and continued surveillance should assist with assessing the impact of new initiatives.
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INTRODUCTION
Injection sites are susceptible to a wide range of bac-
terial infections; as result of poor hygiene injecting
drug users (IDUs) are particularly vulnerable to such
infections. These bacterial infections can result in ill-
nesses ranging from localized infections of the skin
and soft tissues, such as abscesses and cellulitus, to
systemic and toxin-producing infections, such as endo-
carditis and botulism [1, 2]. These infections can be
serious, requiring costly in-patient intervention and
can also lead to death [1, 2]. The prevalence of recent
or current skin and soft tissue infections in IDUs has
been reported to be one in ten in Vancouver and
Sydney [3, 4] ; however, other studies from North
America and in Europe indicate prevalence can be as
high as one in three [5–8]. In North America these
infections are the most common diagnoses in IDUs
presenting to emergency departments [9, 10].
Injection site infections have been associated with
poor hygiene and unsafe injection practices including:
inadequate cleaning of the hands or the injection sites
[11–13] ; needle and syringe re-use [8, 11] ; frequent in-
jection [8, 14–16] ; subcutaneous injection [6, 11] ; the
injection sites used [8, 13, 16] ; the drugs injected [8,
11, 14, 15] ; and drawing blood back into the syringe
repeatedly [9]. Higher levels of these infections have
also been reported to be associatedwith environmental
factors, including poor housing and homelessness
* Author for correspondence : Dr V. D. Hope, Centre for
Infections, Health Protections Agency, 61 Colindale Avenue,
London, NW9 5EQ, UK.
(Email : vivian.hope@hpa.org.uk)
Epidemiol. Infect. (2010), 138, 1510–1518. f Cambridge University Press 2010
doi:10.1017/S0950268810000324
[3, 4, 13], and with gender [3, 4, 8, 14] and source of
income [4].
Since the start of the decade there has been in-
creasing concern in the UK about the extent of bac-
terial infections in IDUs [17–19]. There has been a
marked rise in hospital admissions by drug users with
skin and soft tissue infections, e.g. admissions due to
cutaneous abscesses of trunk or groin increased from
92 to 613 (566%) between ﬁscal years 1997/1998 and
2003/2004 [19]. Annual reports of severe group A
streptococcal infections in IDUs have increased more
than tenfold from less than ten in the mid-1990s to
143 in 2004 [17], although reports have since declined
[17]. There have been outbreaks of Clostridium novyi,
tetanus and wound botulism in IDUs [20–22] in re-
cent years. Community-acquired methicillin-resistant
Staphylococcus aureus infection has also been re-
ported in IDUs [23]. A community recruited study of
IDUs in 2004 found that over a third (36%) of IDUs
in the seven sites sampled in England reported either
an abscess or open wound at an injection site in the
past year, and this study estimated a healthcare burden
cost of between £15.5 and £47 million per annum [8].
These infections are thus likely to place a considerable
burden on health services in the UK, as has been ob-
served elsewhere [5, 6, 16, 24], and this may be in-
creasing [17, 19].
In response to these concerns and the limited avail-
able data on the extent of, or the factors associated
with, injection site infections in IDUs, the UK’s
national annual unlinked anonymous sero-behav-
ioural survey of IDUs added in 2006 the collection of
self-reported data on symptoms likely to be due to
bacterial infection. Using data from this system for
the period 2006–2008, this paper explores the preva-
lence and factors associated with self-reported symp-
toms of injection site infections in IDUs.
METHODS
IDUs have been recruited since 1990 into an annual
voluntary unlinked-anonymous survey across Eng-
land, Wales and Northern Ireland, methodological
details of which have been previously published
[25]. Brieﬂy, drug agencies (both statutory and non-
statutory providers of advice, needle exchange, opiate
substitution therapy, or addiction treatment) invite
clients who have ever injected illicit drugs to partici-
pate in the annual surveys. Those drug users who
agree to take part provide an oral ﬂuid sample and
self-complete a brief surveillance questionnaire. The
oral ﬂuid samples are tested for antibodies to HIV
(anti-HIV), hepatitis C (anti-HCV) and hepatitis B
core antigen (anti-HBc). The agency selection reﬂects
the range of services provided for IDUs as well as re-
ported geographic variations in the extent of injecting
drug use, with the sampling structure reviewed regu-
larly. The survey received multi-site approval from
the London Research Ethics Committee.
The survey’s questionnaire is reviewed regularly,
and since 2006 it has collected information on self-
reported symptoms of injection site infections. The
following question was added: ‘In the last year have
you had a swelling containing pus (abscess), sore, or
open wound at an injection site ’. These symptoms are
most likely to be due to a bacterial infection, although
they could have other causes.
Those taking part in the survey between 2006 and
2008 inclusive, who completed the questionnaire and
reported injecting illicit opiates (e.g. heroin) or stimu-
lants (e.g. crack-cocaine, powder cocaine, or am-
phetamines) in the last year were included in the
analyses. All analyses were undertaken in SPSS ver-
sion 17 (SPSS Inc., USA). Univariate associations
between the reporting of symptoms and the following
variables were examined using the x2 test : demo-
graphic, service use and environmental character-
istics ; the drugs used; region of recruitment ; and
survey year. Those characteristics found to be as-
sociated in the univariate analysis were then entered
using the forward stepwise procedure in SPSS into a
logistic regression model with inclusion assessed using
the likelihood ratio (with the stepwise probability for
inclusion of 0.05 and exclusion of 0.1). As infor-
mation on injecting practice such as frequency of in-
jection, equipment sharing, and the body sites used
for injection was collected only from those who re-
ported injecting in the 4 weeks prior to taking part in
the survey (current IDUs) a second analysis examining
associations between injecting practice and reported
symptoms was undertaken using this subgroup.
RESULTS
Over the 3-year period there were 5209 participations
by drug users who had injected illicit opiates or stimu-
lants in the preceding year. Of these, 25% (1313)
were female, 16% (821) were aged <25 years (mean
age 32.5, median 32 years), and 24% (1230) had been
injecting for <5 years (mean number of years since
ﬁrst injected 10.6, median 9). Just over two-thirds
(69%, 3570) reported currently receiving prescribed
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medication for their drug use (such as opiate substi-
tution therapy), and 89% (4643) reported using a
needle exchange service in the previous 12 months.
Over half (56%, 2898) had injected both opiates and
stimulants during the last year, with two ﬁfths (40%,
2105) having injected only opiates and 4% (206)
having injected only stimulants. During the year pre-
ceding participation 42% (2194) reported being
homeless and 35% (1315) reported having been
imprisoned.
Overall, 36% (1863) report having a ‘swelling con-
taining pus (abscess), sore, or open wound’ at an in-
jection site during the previous 12 months. This varied
little over the 3-year period with 35%, 37% and 34%
reporting this in 2006, 2007 and 2008, respectively
(Table 1). Univariate associations between character-
istics and the reporting of injection site symptoms are
shown in Table 1. In the multivariable analysis a
higher level of reported symptoms was found in 2007
compared to the other 2 years, suggesting a ﬂuctuating
level, but no trend, over time. Reporting symptoms
was less common in the North East region compared
to the other regions of England, Wales and Northern
Ireland (Table 1). The reporting of symptoms in-
creased with number of years injecting, and was higher
in women, those recently homeless, those having re-
cently used a needle exchange service, and those re-
porting injecting both opiates and stimulants, but
lower in those only injecting stimulants (Table 1).
There were 3733 participations by those who re-
ported last injecting during the preceding 4 weeks,
representing 72% of those who had injected during
the 12 months prior to participation. Of these current
IDUs, 24% (913) were female, 17% (623) were aged
<25 years (mean age 32.3, median 32 years), and
24% (893) had been injecting for <5 years (mean
number of years since ﬁrst injected 10.4, median 9).
Those who had injected in the last month had similar
levels of imprisonment and homelessness as those
who had not. However, more of them had used a
needle exchange (93% vs. 80%, x(1)
2 =179.5, P<
0.001), fewer of them were currently receiving pre-
scribed treatment for their drug use (66% vs. 75%,
x(2)
2 =51.9, P<0.001), and more of them were inject-
ing both opiates and stimulants (58% vs. 49%,
x(2)
2 =36.1, P<0.001).
Of those who had injected during the preceding
4 weeks 37% (1375) reported having a ‘swelling
containing pus (abscess), sore, or open wound’ at an
injection site during the previous 12 months. The as-
sociations between reporting a symptom in the last
year and reported injecting practice in the last month
are shown in Table 2. In the multivariable analysis
higher levels of reported symptoms were associated
with the following injecting practices : injecting daily ;
injecting o10 times a day; injecting into the hand,
groin, or legs ; sharing ﬁlters; and reusing water to
ﬂush syringes (Table 2).
DISCUSSION
Symptoms of injection site infections are common
in IDUs throughout England, Wales and Northern
Ireland. These symptoms were reported by just over
a third of IDUs, and while the level ﬂuctuated over
the 3 years examined, there was no clear trend.
These symptoms were associated with injecting both
opiates and stimulants, having been injecting for a
long time, being female, homeless, and with recent use
of a needle exchange. Symptoms were also associated
with more frequent injection, use of particular body
sites for injection, and the reuse of ﬁlters and ﬂushing
water.
The high prevalence of self-reported injection site
infections found in this study, supports previous
ﬁnding from England [8] and also elsewhere [3–7]. The
costs associated with injection site infections are con-
siderable, with conservative estimates for England
suggesting total costs of at least £15.5–19.5 million per
annum, but possibly as high as £47 million in 2006.
Overall healthcare costs related to problematic drug
use, both injecting and non-injecting, in England have
been estimated to be around £500 million per annum
in the ﬁnancial year 2003/2004 [26], with £25 million
of this due to bloodborne viruses (HIV, hepatitis B
and C) in IDUs.
Injection site infections thus place a considerable
burden on the healthcare system that may be greater
than that due to infections by bloodborne viruses. The
high costs associated with injection site bacterial in-
fections are in part likely to be due to delays in seeking
healthcare. Studies suggest that IDUs tend not to seek
timely medical care for their injecting-related health
problems, often resulting in emergency treatment at
considerable cost [8, 10, 24, 27, 28]. The failure to seek
earlier treatment probably reﬂects obstacles, e.g. bar-
riers to accessing care and poor compliance with
medication and follow-up care, and competing pri-
orities such as obtaining money and acquiring and
using drugs [10, 24, 28, 29]. Thus, the high levels of
reported symptoms found here are a concern and high-
light the need for interventions. Targeted prevention
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Table 1. Factors associated with a self-reported abscess, sore or open wound at injecting site in the previous
12 months: injecting drug users, 2006–2008
Characteristic
Abscess, sore or open wound
Adjusted odds
ratio (95% CI)Yes (%, n) Total
Gender Male 34% 1338 3896 1.00
Female 40% 525 1313 1.43 (1.25–1.64)
x2=13.61 P<0.001
Age (yr) <25 30% 249 821
#
25–29 33% 397 1214
30–34 35% 410 1174
9>>=
>>;35–39 40% 419 1045
o40 41% 388 955
x2=34.24 P<0.001
Region/country East England 35% 82 233 1.00
London 41% 290 708 1.14 (0.83–1.56)
South East 40% 345 866 1.11 (0.82–1.51)
South West 40% 250 620 1.20 (0.87–1.65)
West Midlands 33% 119 356 0.93 (0.65–1.33)
North West 38% 282 747 0.98 (0.71–1.34)
Yorkshire & Humber 33% 47 141 0.93 (0.59–1.45)
East Midlands 31% 160 516 0.82 (0.59–1.15)
North East 26% 133 507 0.67 (0.47–0.94)
Wales 31% 98 320 0.81 (0.56–1.17)
Northern Ireland 29% 57 195 0.83 (0.55–1.26)
x2=55.14 P<0.001
Survey year 2006 35% 587 1695 1.00
2007 38% 718 1893 1.18 (1.03–1.36)
2008 34% 558 1621 1.00 (0.86–1.15)
x2=6.08 P=0.05
Years since ﬁrst injected <5 years 29% 361 1230 1.00
5–9 years 35% 510 1448 1.30 (1.10–1.54)
10–14 years 36% 424 1172 1.38 (1.15–1.64)
o15 years 42% 568 1359 1.74 (1.46–2.06)
x2=43.82 P<0.001
Drug types used last year Opiate, no stimulant 33% 688 2105 1.00
Stimulant, no opiate 19% 39 206 0.49 (0.34–0.71)
Stimulant and opiate 39% 1136 2898 1.24 (1.09–1.40)
x2=48.98 P<0.001
Prescribed treatment
for their drug use
Never in treatment 29% 206 706
#Currently scripted 37% 1321 3570
)
Previously scripted 36% 336 933
x2=15.74 P<0.001
Used needle exchange
last year
No 27% 150 566 1.00
Yes 37% 1713 4643 1.65 (1.35–2.01)
x2=23.72 P<0.001
Anti-HIV status Positive 46% 26 56
o
#Negative 36% 1837 5153
x2=2.80 P=0.09
Anti-HCV status Positive 39% 854 2163
o
#Negative 33% 1009 3046
x2=22.25 P<0.001
Homeless last year No 34% 1022 3015 1.00
Yes 38% 841 2194 1.18 (1.05–1.33)
x2=10.87
Ever imprisoned No 34% 536 1570
$Yes, not last year 37% 844 2289
)
Yes, in last year 36% 469 1315
x2=3.03 P=0.22
CI, Conﬁdence interval.
# Not in ﬁnal multivariable model.
$ Not entered into multivariable analysis.
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Table 2. Injecting practices is last month associated with a self-reported abscess, sore or open wound at
injecting site during the previous 12 months, injecting drug users 2006–2008
Characteristic
Abscess, sore or open wound
Adjusted odds
ratio (95% CI)Yes (%, n) Total
Times injected last full day 1 30% 321 1068 1.00
2–4 38% 856 2252 1.14 (0.95–1.36)
5–9 45% 159 352 1.32 (0.99–1.76)
o10 64% 39 61 2.99 (1.65–5.44)
x2=52.20 P<0.001
Number of days injected
last 4 weeks
<14 32% 411 1291 1.00
14–27 36% 285 800 1.07 (0.87–1.31)
o28 41% 679 1642 1.23 (1.03–1.48)
x2=28.77 P<0.001
Shared needles and
syringes last 4 weeks
No 35% 1014 2917
o
#Yes 44% 361 816
x2=24.62 P<0.001
Shared spoons last 4 weeks No 33% 767 2340
o
#Yes 44% 608 1393
x2=44.34 P<0.001
Shared ﬁlters last 4 weeks No 33% 831 2525 1.00
Yes 45% 544 1208 1.31 (1.09–1.59)
x2=51.61 P<0.001
Shared water for drug
preparation last 4 weeks
No 35% 1068 3057
o
#Yes 45% 307 676
x2=26.12 P<0.001
Shared water for ﬂushing
works last 4 weeks
No 34% 996 2914 1.00
Yes 46% 379 819 1.28 (1.03–1.59)
x2=40.21 P<0.001
Injected into arms last 4 weeks Yes 36% 836 2352
o
#No 39% 539 1381
x2=4.54 P=0.03
Injected in to hands last 4 weeks Yes 48% 448 936 1.54 (1.29–1.82)
No 33% 927 2797 1.00
x2=65.32 P<0.001
Injected in to groin last 4 weeks Yes 39% 491 1248 1.28 (1.09–1.51)
No 36% 884 2485 1.00
x2=5.07 P=0.02
Injected in to legs last 4 weeks Yes 62% 426 683 3.24 (2.69–3.90)
No 31% 949 3,050 1.00
x2=234.33 P<0.001
Injected in to feet last 4 weeks Yes 58% 245 422
#No 34% 1130 3311
o
x2=92.11 P<0.001
Gender Male 35% 989 2820 1.00
Female 42% 386 913 1.41 (1.19–1.66)
x2=15.40 P<0.001
Region/country East England 34% 48 142 1.00
London 45% 205 458 1.52 (1.00–2.33)
South East 41% 272 660 1.32 (0.88–1.98)
South West 40% 182 454 1.27 (0.83–1.94)
West Midlands 36% 99 278 1.26 (0.80–1.98)
North West 40% 224 561 1.40 (0.93–2.12)
Yorkshire & Humber 36% 27 74 1.31 (0.70–2.46)
East Midlands 30% 121 406 0.82 (0.53–1.27)
North East 25% 105 415 0.73 (0.47–1.14)
Wales 31% 62 201 0.99 (0.61–1.62)
Northern Ireland 36% 30 84 1.67 (0.92–3.03)
x2=58.41 P<0.001
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and healthcare have been shown to reduce emergency
department attendances, the need for surgery, and in-
patient days [30, 31].
The current study found that frequent injection, the
use of certain injection sites (hand, groin, legs), and the
reuse of injecting paraphernalia were all associated
with reporting symptoms of injection site infections
during the last year. Previous studies have found
similar associations [8, 11, 12, 14, 15], and also as-
sociations with inadequate washing of hands or clean-
ing of the injection sites [6, 11, 12], and the use of
multiple injection sites [11, 12]. The associations with
particular injection sites needs further examination,
but may reﬂect some of these sites being more diﬃcult
to keep clean or the need to use certain sites due to
others becoming unusable due to vascular damage,
injury, or infection. The association with femoral
(‘groin’) injection in the current study is of particular
concern as this practice has become more common in
the UK over the last decade [32], with indications of
increased hospital admissions related to femoral in-
jection in IDUs [19].
The association with injecting both opiates and
stimulants is a concern. The mostly widely injected
stimulant in the UK is crack-cocaine, with this often
being injected either in combination or in parallel with
heroin. A previous study in England found that those
reporting crack-cocaine use also reported higher
levels of injection site infections, and studies elsewhere
have observed similar associations with injection of
cocaine [7, 10] and heroin and cocaine combinations
[11, 15]. There is also evidence that suggests that
crack-cocaine use, which has been associated with
risky behaviours [32, 33], has become more common
in the UK in recent years [34].
Women were more likely to report an injection site
infection, and this has also been found in other studies
[7, 8, 11, 15]. This could reﬂect a greater awareness of
infections, and/or a greater vulnerability to injection
site infections in female injectors [14]. As women are
more likely to be injected by others, or to need as-
sistance with injecting, it has been argued that as a
result they may be at increased risk of exposure to
contaminants [4]. The reason for the diﬀerence in
prevalence with gender needs further investigation.
The positive association with needle exchange use
in the last year is an interesting, if counter-intuitive,
ﬁnding. However, this needs to be interpreted with
care as those reporting needle exchange use in the
last year will include not only those making extensive
regular use of needle exchange services but also those
making irregular or limited use of these services.
Table 2 (cont.)
Characteristic
Abscess, sore or open wound
Adjusted odds
ratio (95% CI)Yes (%, n) Total
Survey year 2006 36% 450 1236
#2007 39% 529 1353
)
2008 35% 396 1144
x2=5.50 P=0.064
Drug types used last year Opiate, no stimulant 34% 484 1416 1.00
Stimulant, no opiate 21% 30 144 0.47 (0.30–0.75)
Stimulant and opiate 40% 861 2173 1.06 (0.91–1.24)
x2=27.39 P<0.001
Years since ﬁrst injected <5 years 30% 266 893 1.00
5–9 years 36% 385 1055 1.27 (1.03–1.56)
10–14 years 38% 317 839 1.24 (1.00–1.54)
o15 years 43% 407 946 1.46 (1.18–1.82)
x2=35.01 P<0.001
Used needle exchange last year No 28% 75 270 1.00
Yes 38% 1300 3463 1.44 (1.07–1.93)
x2=10.26 P=0.001
Homeless last year No 35% 746 2145
o
#Yes 40% 629 1588
x2=9.15 P=0.002
CI, Conﬁdence interval.
# Not in ﬁnal multivariable model.
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Studies suggest the consistent high coverage of inter-
ventions like needle exchange is needed for them to be
eﬀective against bloodborne viruses [35–37], and it is
likely that such coverage issues would similarly aﬀect
their impact on injection site infections. It should also
be noted that not all needle exchanges in the UK
provide a full range of injecting equipment, and that
some IDUs may also have accessed a needle exchange
service either as a route to wound care or as a pre-
ventive measure following an injection site infection.
However, this association requires further examin-
ation.
In our study homelessness was associated with
higher rates of reporting of injection site symptoms,
while a previous study in England did not ﬁnd any
association with homelessness [8]. Studies elsewhere
have found similar associations with poor housing
and homelessness [3, 4, 13]. Homelessness is possibly
an indicator of increased rates of injection in public or
semi-public environments, which has been related to
poor injection hygiene [11, 12].
Preventive interventions should thus focus on fur-
ther reducing the re-use of injecting equipment, and
target frequent injectors, those injecting into groin,
legs or hand, using both opiates and stimulants, and
female injectors ; these interventions should also aim
to reach those who are homeless. Development of
community-based interventions, such as targeted
wound clinics, may be eﬀective [30, 31]. While further
work needs to identify, develop, and evaluate suitable
interventions, our ﬁndings suggest a need to focus on
improving injection hygiene, the better management
of the body sites used for injection, and access to ser-
vices, including the provision of paraphernalia and
sterile water.
The 3 years’ data presented here did not indicate
any overall upwards or downwards trend in symp-
toms associated with injection site infection, with the
level much the same as that found in a study of cur-
rent IDUs recruited in the community at seven sites in
England conducted 2 years earlier [8]. This suggests
that the recent level of symptoms may have been
relatively stable ; however, this may not remain so.
The concerns expressed earlier this decade about the
extent of infections in IDUs [17–19, 21–23] have re-
sulted in increased eﬀorts to reduce infections, both
viral and bacterial. The National Institute for Health
and Clinical Excellence has recently issued guidance
on optimizing needle exchange provision [38] and a
national awareness and information campaign has
recently been launched in England [39]. Ongoing
surveillance of symptoms of injection site infections
may shed light on the impact of these initiatives.
It is important to consider the limitations and gen-
eralizability of these ﬁndings. Self-reported symptoms
of injection site infections were used in this study.
While some may question the accuracy of these,
studies have shown good agreement between self-
reported symptoms and clinical diagnosis [24]. The
comparative rarity, marginalization and illegal nature
of injecting drug use impedes the recruitment of a
representative sample of injectors. This study aimed
to minimize sampling biases andmaximize representa-
tiveness by using an established survey utilizing wide-
spread service provision as a sampling structure.
However, bias might arise if those using services
where the sampling occurred were either at higher or
lower risk than the overall IDU population. Those
not in contact with services might be those most
marginalized and so at highest risk but, alternatively,
they may be those most stable and integrated with
well-controlled drug use and so at low risk. Both of
these groups are possibly under-represented; however,
surveys recruiting independently of services through
community settings, using a range of sampling ap-
proaches, ﬁnd that most IDUs recruited in the UK
have, or have recently had, service contact [40].
Taken together these ﬁndings suggest injection site
infections are a common experience in IDUs in
England, Wales and Northern Ireland, and that the
resultant healthcare burden is substantial. Further
research is also needed to explore issues around the
robustness of self-reports and the relationship be-
tween reported symptoms and actual infections.
Moreover, interventions need to be developed and
piloted to reduce the level of infections. Continued
surveillance should provide the means to shed light on
the impact of new initiatives to reduce infections in
IDUs.
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